Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 11/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.42 |
| ▸ | MC4R | P32245 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | IL1B | P01584 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL556341 | 0.88 | REN (0.43) | RENKCNH2CYP3A4MC4RJAK2 | |
| SCHEMBL555714 | 0.82 | REN (0.60) | RENKCNH2CYP3A4MC4RALK | |
| SCHEMBL556589 | 0.82 | REN (0.60) | RENKCNH2CYP3A4MC4RALK | |
| SCHEMBL557036 | 0.80 | REN (0.60) | RENKCNH2CYP3A4RORC | |
| SCHEMBL555764 | 0.78 | REN (0.42) | RENKCNH2CYP3A4 | |
| SCHEMBL556160 | 0.78 | REN (0.64) | RENKCNH2CYP3A4 | |
| SCHEMBL555684 | 0.78 | REN (0.56) | RENKCNH2CYP3A4JAK2JAK1 | |
| SCHEMBL556170 | 0.76 | REN (0.69) | RENKCNH2CYP3A4ALK | |
| SCHEMBL555742 | 0.76 | REN (0.62) | RENKCNH2CYP3A4ALKRORC | |
| SCHEMBL555815 | 0.75 | REN (0.61) | RENKCNH2CYP3A4ALKRORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | REN 1/4885KCNH2 1198/4885CYP3A4 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.